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Abstract. Neuropsychiatric symptoms (NPS) have been frequently described in Parkinson’s disease (PD), even in the earliest
stages of the disease. Recently the construct of mild behavioral impairment (MBI) has been proposed as an at-risk state for
incident cognitive decline and dementia. The aim of the present study is to evaluate the prevalence and associated factors of
MBI in PD. Cross-sectional data from 429 consecutive PD patients enrolled in the PArkinson’s disease COgnitive impairment
Study (PACOS) were included in the study. All subjects underwent neuropsychological assessment, according to the MDS
Level II criteria. NPS were evaluated with the Neuropsychiatric Inventory. Multivariate logistic regression models were
used to evaluate clinical and behavioral characteristics, which are associated with PD-MBI. PD-MBI was ascertained in 361
(84.1%) subjects of whom 155 (36.1%) were newly diagnosed patients (disease duration ≤1 year) and 206 (48.0%) had a
disease duration >1 year. Furthermore, 68 (15.9%) out of 429 subjects were PDw (without MBI). Across the MBI domains,
Impulse Dyscontrol was significantly more prevalent among PD-MBI with disease duration >1 year than newly diagnosed
patients. The frequency of Social Inappropriateness and Abnormal Perception significantly increased throughout the entire
PD-MBI sample with increasing Hoehn and Yahr (H&Y) stages. PD-MBI in newly diagnosed PD was significantly associated
with H&Y stage (OR 2.35, 95% CI 1.05–5.24) and antidepressant drug use (OR 2.94, 95% CI 0.91–9.47), while in patients
with a disease duration >1 year was associated with UPDRS-ME (OR 3.37, 95% CI 1.41–8.00). The overall MBI frequency
in the PACOS sample was 84% and 36% among newly diagnosed patients. The presence of MBI mainly related to motor
impairment and disability.
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INTRODUCTION27
Neuropsychiatric symptoms (NPS) are frequent28
in dementia and mild cognitive impairment (MCI),29
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relating to a worse prognosis [1, 2]. Similarly, NPS 30
have been frequently described in Parkinson’s disease 31
(PD) even in the early, untreated phases of the dis- 32
ease, being associated with a reduced quality of life 33
and advanced disease [3, 4]. Nearly 90% of patients 34
with PD dementia had at least one NPS, with depres- 35
sion, apathy, anxiety, and hallucinations being the 36
most prevalent symptoms [3]. Recently, the Interna- 37
tional Society to Advance Alzheimer’s Research and 38
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Treatment (ISTAART) has proposed the new con-39
struct of mild behavioral impairment (MBI). This40
is characterized by later life-acquired NPS of dif-41
ferent severity and it is considered an at-risk state42
for incident cognitive impairment and dementia [9].43
Ismail et al. have identified five behavioral domains44
included within the MBI spectrum: Decreased Moti-45
vation, Affective Dysregulation, Impulse Dyscontrol,46
Social Inappropriateness, and Abnormal Perception.47
These behavioral changes interfere minimally with48
interpersonal relationships and affected individuals49
substantially maintain their independence regard-50
ing daily activities [9]. Subsequently, Sheikh et al.51
[10] have deployed ten behavioral symptoms rated52
to the Neuropsychiatric Inventory (NPI) [11] to53
operationalize the ISTAART-AA MBI domains. Cur-54
rently, the concept of MBI is evaluated in subjects55
with subjective cognitive decline (SCD) and MCI,56
preclinical and a prodromal phase of Alzheimer’s57
disease, respectively [12]. MBI is present in approx-58
imately 80% of the population, being more prevalent59
in MCI than in subjects with SCD (85.3 versus60
76.5, respectively) [10]. Furthermore, the presence61
of MBI without cognitive impairment determines62
a higher risk of conversion to dementia than the63
presence of MCI without psychiatric complaints64
[13, 14].65
Cognitive impairment and dementia have been66
described with a high frequency during the course67
of PD, being associated with age, disease duration,68
disease severity, and a poor outcome [3]. Validated69
clinical criteria for MCI in PD (PD-MCI) have been70
recently recommended [5], with a mean point preva-71
lence for PD-MCI of nearly 27% [6]. PD-MCI has72
been found to be directly associated with age and73
motor impairment, while an inverse association has74
been observed between educational level and MCI75
[7]. PD-MCI subjects have a greater NPS burden than76
PD without cognitive impairment, and depression,77
sleep disturbance, anxiety, and apathy were the most78
common NPS in PD-MCI [8].79
There are no studies evaluating the frequency and80
associated clinical features of MBI in subjects with81
PD, and thus the relationship between MBI and MCI82
in PD has not been evaluated. The aims of this study83
were: 1) to evaluate the prevalence and associated84
factors of MBI in PD subjects; 2) to investigate the85
relationship between MBI and MCI in PD patients;86
and 3) to examine whether the prevalence and risk87
factors of MBI differ according to disease duration88
(i.e., patients with a disease duration ≤1 year versus89
patients with a disease duration >1 year).90
MATERIALS AND METHODS 91
The PArkinson’s disease COgnitive impairment 92
Study (PACOS) is a large, cross-sectional, hospital- 93
based study, involving two Movement Disorder 94
Centers in southern Italy (the University Hospitals 95
of Catania and Palermo). The primary endpoint of 96
the PACOS was to evaluate the burden of PD-MCI; 97
the secondary endpoints were the evaluation of asso- 98
ciated/risk factors and biomarkers for PD-MCI and 99
its progression to PD dementia (PDD) [7]. With 100
reference to the present study, 429 subjects with 101
PD (according to the UK PD Society Brain Bank 102
criteria [15]) were included and they had been con- 103
secutively evaluated for cognitive impairment over 104
a 4-year period (2014–2017). The exclusion criteria 105
were the presence of PDD [16], secondary parkin- 106
sonism and Parkinson-plus syndromes. All patients 107
underwent an extensive physical, neurological, and 108
neuropsychological examination, laboratory testing, 109
and computed tomography or magnetic resonance 110
imaging. Data relating to age at onset and disease 111
duration in years were collected for each patient. 112
Motor evaluation included the Unified Parkinson’s 113
Disease Rating Scale-Motor Examination (UPDRS- 114
ME) [17] and the Hoehn and Yahr scale (H&Y) (stage 115
I-III) [18]. 116
According to the most prominent motor pheno- 117
type at onset of PD, patients were classified as: 118
Postural Instability and Gait Difficulty, Tremor Dom- 119
inant, or of a Mixed Type [19]. The Basic Activities 120
of Daily Living (BADL) [20] and the Instrumental 121
Activities of Daily Living (IADL) [21] were used 122
to evaluate functional ability (scored as the number 123
of items lost for each scale). The overall burden of 124
dopaminergic drugs was evaluated with the total daily 125
Levodopa Equivalent Dose (LED) [22]. The Cumula- 126
tive Illness Rating Scale (CIRS) was used to evaluate 127
somatic comorbidity, considering the total score and 128
the severity index (number of systems with score ≥3) 129
[23]. All PD subjects underwent a neuropsycholog- 130
ical assessment when in “on” state. PD-MCI was 131
diagnosed according to the Movement Disorder Soci- 132
ety (MDS) Task Force, Level II criteria [5]. Subjects 133
underwent a complete neuropsychological battery, 134
exploring five cognitive domains: memory, attention, 135
visuospatial and executive functioning, and language. 136
The details of the cognitive assessment have already 137
been described elsewhere [24]. Neuropsychological 138
performance was considered as impaired when sub- 139
jects scored two standard deviations below normality 140
cut-off values. 141
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NPS and their severity were assessed by the142
NPI, a fully structured caregiver interview measur-143
ing 12 behavioral symptoms [11]. Frequency and144
severity scores were multiplied for each symptom145
to obtain a composite score ranging from 0 to146
12. As suggested by Sheikh et al., MBI domains147
were computed using NPI subscores as follows: 1)148
Decreased Motivation (NPI: apathy/indifference); 2)149
Affective Dysregulation (NPI: depression/dysphoria,150
anxiety, elation/euphoria); 3) Impulse Dyscontrol151
(NPI: agitation/aggression, irritability, liability, aber-152
rant motor behavior); 4) Social Inappropriateness153
(NPI: disinhibition); and 5) Abnormal Perception154
(NPI: delusions, hallucinations) [10]. Just one behav-155
ioral symptom was sufficient to meet the MBI domain156
criteria. Thus, if at least one of the five domains157
was present, an MBI diagnosis was fulfilled. To fit158
the MBI construct, which requires six months of159
new onset symptoms, a modified reference range of160
six months was used to ascertain each NPI symp-161
toms, as previously detailed. Regarding functional162
abilities, no impairment or minimal impairment of163
BADL was considered as inclusion criteria. Con-164
trarily, IADL impairment occurs frequently in PD165
due to motor rather than cognitive impairment and166
this feature was not adopted for MBI classification167
[8]. Finally, patients were classified as follows: PDw168
(without behavioral impairment) and PD-MBI (with169
behavioral impairment), stratified by disease duration170
(newly diagnosed: patients with a disease duration≤1171
year and patients with a disease duration >1 year). All172
subjects provided written informed consent prior to173
entering the study, which was approved by the local174
Ethics Committee, in accordance with the Declara-175
tion of Helsinki.176
Statistical analysis177
Statistical analyses were carried out using STATA178
v14.2 software. Data cleaning was performed prior179
to data analysis, considering range and consistence180
checks. Normal distribution and homogeneity of vari-181
ables were tested with Kolmogorov-Smirnov and182
Levene’s test respectively. Mean data (Standard Devi-183
ation, SD) were compared using a one-way analysis184
of variance (ANOVA) with Scheffe’s post hoc test for185
multiple comparisons, while medians (Interquartile186
Range, IQR) were analyzed with the Mann-Whitney187
test. The chi-square test was used to compare cate-188
gorical variables.189
In order to evaluate the possible predictors for190
MBI, an unconditional logistic regression analysis191
was performed using PDw as the reference category 192
and stratifying subjects according to disease duration 193
(≤1 versus >1 year). Covariates, which were signif- 194
icantly associated with study outcomes (PD-MBI) 195
after univariate analysis (p < 0.1), were entered into 196
the multiple logistic regression, which includes the 197
following as a priori confounders: age, sex, educa- 198
tion, and MCI. Furthermore and to avoid collinearity 199
between CIRS neurologic/psychiatric items and PD- 200
MBI, the CIRS total score and severity index were 201
calculated, excluding the neurological and psychi- 202
atric items. 203
The model was manually constructed, using 204
the likelihood ratio test in order to compare the 205
log-likelihood of the model with and without a spe- 206
cific variable. Whenever quantitative variables were 207
dichotomized (UPDRS-ME and LED), the cut-offs 208
were derived from the pooled distribution (median 209
value of the pooled distribution). The possible inter- 210
action was also evaluated by the likelihood ratio test 211
(test of violation of proportional odds). Regarding 212
quantitative exposure, the test for linear trend was 213
performed to evaluate the linear or trend effect. The 214
results are presented as odds ratios (OR) with 95% 215
confidence intervals (95% CI). 216
RESULTS 217
Clinical characteristics and descriptive features 218
of MBI in PD patients 219
Four hundred twenty-nine PD patients were 220
enrolled in the study (59.9% male, mean age 221
68.2 ± 9.4) with a mean disease duration of 2.9 ± 3.6 222
and a median UPDRS-ME of 21 (range 14–19) 223
(see Table 1). Of the 429 enrolled patients, 361 224
fulfilled the criteria for MBI, providing an overall 225
frequency of 84.1%. One hundred fifty-five (36.1%) 226
of the 361 PD-MBI and 33 (48.5%) of 68 PDw were 227
newly diagnosed patients (disease duration ≤1 year). 228
Overall, there were 165 subjects (38.5%) with MCI 229
(57% male, median education 5 [range 3–8]), mean 230
age 70.5 ± 8.2, mean disease duration 3.3 ± 3.7 and 231
median UPDRS-ME 25 [range 18–33]). Regarding 232
the entire sample, a borderline significant higher fre- 233
quency of MCI was recorded among PD subjects with 234
MBI with respect to PDw (PD-MBI with MCI = 40% 235
versus PDw with MCI = 27.9%, p-value 0.054). 236
The mean scores for each NPI symptom and 237
the frequency of each MBI domain are depicted 238
in Table 2. Specifically, Affective Dysregulation, 239
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Table 1
Demographic and clinical characteristics of PDw, PD-MBI ≤ 1 y, and PD-MBI > 1 y
Total PDw PD-MBI ≤ 1 y PD-MBI > 1 y P
n = 429 (100%) n = 68 (15.9%) n = 155 (36.1%) n = 206 (48.0%)
Age (y), mean (SD) 68.2 (9.4) 66.0 (11.8) 68.1 (8.6) 69.0 (9.0) 0.079
Education (y), median (range) 5 (3–12) 6 (5–13) 6 (5–13) 5 (3–10) 0.482
Male, n (%) 257 (59.9) 46 (67.6) 91 (58.7) 120 (58.2) 0.364
Disease duration (y), mean (SD) 2.9 (3.6) 2.5 (3.5) 0.3 (0.5) 5.1 (3.6) <0.001
Motor phenotype, n (%)
-TD 116 (27.0) 24 (35.3) 47 (30.3) 45 (21.8) 0.156
-Mixed 48 (11.2) 6 (8.8) 19 (12.3) 23 (11.2)
-PIGD 265 (61.8) 38 (55.9) 89 (57.4) 138 (67.0)
H&Y, median (range) 2 (1.5–2.5) 2 (1–2.5) 2 (1.5–2.5) 2 (1–2.5) 0.032
UPDRS-ME, median (range) 21 (14–29) 17 (12–23) 19 (13–25) 25 (19–33) <0.001
UPDRS-ME ≥ 21, n (%) 224 (52.2) 24 (35.3) 63 (40.6) 137 (66.5) <0.001
Total LED mg/die, median (range) 300 (200–400) 300 (200–325) 250 (200––375) 375 (250–500) <0.001
Total LED ≥ 300 mg/die, n (%) 261 (60.8) 35 (51.5) 75 (48.4) 151 (73.3) <0.001
Antipsycotic drug use, n (%) 20 (4.9) 0 (0) 8 (5.2) 12 (5.8) 0.133
Antidepressant drug use, n (%) 115 (26.8) 9 (13.2) 47 (30.3) 59 (28.6) 0.021
Anxiolytics drug use, n (%) 112 (26.1) 10 (14.7) 48 (31.0) 54 (26.2) 0.039
CIRS total, mean (SD) 15.8 (2.6) 15.0 (2.3) 16.2 (2.7) 15.7 (2.5) 0.008
CIRS index, mean (SD) 1.2 (1.2) 0.9 (1.1) 1.4 (1.3) 1.2 (1.2) 0.019
MCI, n (%) 165 (38.5) 19 (27.9) 51 (32.9) 95 (46.1) 0.006
PD, Parkinson’s disease; MBI, mild behavioral impairment; PDw, Parkinson’s disease without MBI; PD-MBI ≤ 1 y, PD with MBI with
disease duration ≤1 year; PD-MBI > 1 y, PD with MBI with disease duration >1 year; TD, tremor dominant; PIGD, postural instability gait
difficulty; H&Y, Hohen and Yahr; UPDRS-ME, Unified Parkinson’s Disease Rating Scale, Motor Examination; LED, levodopa equivalent
dose; CIRS, Cumulative Illness Rating Scale; MCI, mild cognitive impairment.
Decreased Motivation, and Impulse Dyscontrol were240
in decreasing order the most prevalent MBI domains241
in both MBI groups. PD-MBI with disease duration242
>1 year revealed a significantly higher frequency of243
Impulse Dyscontrol than PD-MBI newly diagnosed244
(47.6% versus 35.5%, p = 0.021).245
Thereafter, the frequency of each MBI domain in246
PD patients, stratified by motor disability according247
to H&Y stage (H&Y 1–1.5, H&Y 2–2.5, and H&Y248
3) was evaluated. Overall, the impairment in each249
domain increases with increasing H&Y stage (see250
Fig. 1) except for Affective Dysregulation. However,251
significant differences were found only for Social252
Inappropriateness (p≤ 0.001) andAbnormal Percep-253
tion (p = 0.004).254
Factors associated with PD-MBI255
Univariate and multivariate analysis were con-256
ducted to explore associated factors for PD-MBI,257
considering PDw as the reference group and strat-258
ifying by disease duration (≤1 versus >1 year)259
(see Table 3). The univariate analysis relating to260
newly diagnosed patients revealed significant asso-261
ciations with age (OR 1.06, 95% CI 1.01–1.10),262
H&Y (OR 2.51, 95% CI 1.22–5.17), antidepressant263
drug use (OR 3.15, 95% CI 1.05–9.48), anxiolyt-264
ics drug use (OR 2.51, 95% CI 0.91–6.90), CIRS265
Table 2
Mean scores of NPI symptoms and frequency of MBI domains in
PD-MBI ≤ 1 y and PD-MBI > 1 y
NPI symptoms PD-MBI ≤ 1 y PD-MBI > 1 y p
(n = 155) (n = 206)
mean (SD) mean (SD)
Delusions 0.25 (1.29) 0.18 (1.04) 0.557
Hallucinations 0.34 (1.24) 0.53 (1.67) 0.230
Agitation 0.68 (2.05) 0.72 (1.75) 0.838
Depression 4.04 (3.07) 3.44 (3.26) 0.076
Anxiety 3.98 (3.20) 3.37 (3.24) 0.075
Euphoria 0.06 (0.66) 0.15 (0.83) 0.291
Apathy 2.61 (3.11) 2.54 (2.87) 0.831
Disinhibition 0.19 (1.28) 0.14 (0.90) 0.646
Irritability 1.50 (2.76) 1.53 (2.56) 0.908
Aberrant motor
behavior
0.38 (1.60) 0.30 (1.27) 0.577
MBI domains n % n %
DM 78 (50.3%) 111 (53.9%) 0.503
AD 142 (91.6%) 180 (87.4%) 0.200
ID 55 (35.5%) 98 (47.6%) 0.021
SI 4 (2.6%) 9 (4.4%) 0.367
AP 20 (12.9%) 33 (16,0%) 0.408
NPI, Neuropsychiatric Inventory; PD, Parkinson’s disease; MBI,
mild behavioral impairment; PD-MBI ≤ 1 y, PD with MBI with
disease duration≤1 year; PD-MBI > 1 y, PD with MBI with disease
duration >1 year; DM, decreased motivation; AD, affective dys-
regulation; ID, impulse dyscontrol; SI, social inappropriateness;
AP, abnormal perception.
total (OR 1.21, 95% CI 1.03–1.42), and CIRS index 266
(OR 1.44, 95% CI 1.03–2.03). On the contrary, there 267
was no association with MCI (OR 1.82, 95%CI 268
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Fig. 1. Frequency of each MBI domains, stratified by H&Y stage MBI, mild behavioral impairment; H&Y, Hohen and Yahr; DM, Decreased
Motivation; AD, Affective Dysregulation; ID, Impulse Dyscontrol; SI, Social Inappropriateness; AP, Abnormal Perception.
Table 3
Univariate and multivariate analysis of PD-MBI ≤ 1 y versus PDw and PD-MBI > 1 y versus PDw
PD-MBI ≤ 1 y versus PDw ≤ 1 PD-MBI > 1 y versus PDw > 1 y
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Age, y (per y increase) 1.06 (1.01–1.10)∗∗∗ 1.04 (0.99–1.08) 1.01 (0.96–1.04) 0.99 (0.96–1.04)
Education, y (per y increase) 0.95 (0.88––1.03) 1.01 (0.92–1.10) 0.99 (0.92–1.08) 1.02 (0.94–1.12)
Gender, (male versus female) 0.53 (0.23–1.22) 0.70 (0.29–1.73) 0.82 (0.39–1.73) 0.83 (0.38–1.82)
Disease duration, y (per y increase) 1.93 (0.79–4.74) 1.04 (0.93–1.16)
H&Y, (per unit increase) 2.51 (1.22–5.17)∗∗ 2.35 (1.05–5.24)∗∗ 1.88 (0.93–3.77)∗ 0.91 (0.39–2.08)
UPDRS-ME, median (per unit increase) 1.03 (0.99–1.07) 1.08 (1.03–1.13)∗∗∗
UPDRS-ME, (≥21 versus < 21) 1.20 (0.55–2.61) 3.81 (1.79–8.10)∗∗∗ 3.37 (1.41–8.00)∗∗∗
Total LED mg/die, median (per unit increase) 1.01 (0.99–1.01) 1.01 (1.01–1.02)∗∗ 1.01 (0.99–1.01)
Total LED mg/die, (≥300 versus < 300) 1.27 (0.60–2.72) 1.83 (0.87–3.85)
Antidepressant drug use 3.15 (1.05–9.48)∗∗ 2.94 (0.91–9.47)∗ 2.41 (0.89–6.50)∗ 1.80 (0.64–5.09)
Anxiolytics drug use 2.51 (0.91–6.90)∗ 2.19 (0.74–6.45) 2.13 (0.79–5.77)
CIRS total 1.21 (1.03–1.42)∗∗ 1.12 (0.96–1.32)
CIRS Index 1.44 (1.03–2.03)∗∗ 1.24 (0.88–1.75) 1.31 (0.93–1.85)
MCI 1.82 (0.74–4.48) 1.10 (0.40–3.01) 1.64 (0.77–3.47) 1.34 (0.59–3.03)
PD, Parkinson’s disease; MBI, mild behavioral impairment; PDw, Parkinson’s disease without MBI; PD-MBI ≤ 1 y, PD with MBI with disease
duration ≤1 year; PD-MBI > 1 y, PD with MBI with disease duration >1 year; H&Y, Hohen and Yahr; UPDRS-ME, Unified Parkinson’s
Disease Rating Scale, Motor Examination; LED, levodopa equivalent dose; CIRS, Cumulative Illness Rating Scale; MCI, mild cognitive
impairment. ∗<0.1; ∗∗<0.05; ∗∗∗<0.01. Age, sex, education, and MCI were considered as a priori confounders.
0.74–4.48). However, only H&Y (OR 2.35, 95% CI269
1.05–5.24) and antidepressant drug use (OR 2.94,270
95% CI 0.91–9.47) were still significantly associ-271
ated with PD-MBI after multivariate analysis. The272
univariate analysis regarding patients with disease273
duration >1 year revealed significant associations274
with H&Y (OR 1.88, 95% CI 0.93–3.77), UPDRS-275
ME (OR 1.08, 95% CI 1.03–1.13), UPDRS-ME ≥ 21276
(OR 3.81, 95% CI 1.79–8.10), total LED (OR 1.01,277
95% CI 1.01–1.02), and antidepressant drug use (OR278
2.41, 95% CI 0.89–6.50). Again, there was no asso-279
ciation with MCI (OR 1.64, 95%CI 0.77–3.47). At280
multivariate analysis, only UPDRS-ME ≥ 21 (OR 281
3.37, 95% CI 1.41–8.00) was still significantly asso- 282
ciated with PD-MBI. 283
MCI was marginally significantly associated with 284
MBI throughout the whole PD-MBI group only at 285
the univariate analysis, giving an unadjusted OR of 286
1.75 (95% CI 0.99–3.09), which disappear after con- 287
trolling for covariates (OR 1.29, 95% CI 0.68–2.42). 288
However, when the MBI sample was stratified by 289
disease duration (≤1 versus >1 year), MCI was not 290
significantly associated with PD-MBI in either group 291
(see Table 3). 292
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DISCUSSION293
This study evaluated the frequency and asso-294
ciated factors of MBI in PD subjects. The main295
results were: 1) the frequency of MBI was 84.1%296
throughout the whole sample of PD and 36.1% in297
newly diagnosed patients; 2) with reference to a298
specific behavioral domain, Affective Dysregulation299
and Decreased Motivation were in decreasing order300
the most frequent domains, while Impulse Dyscon-301
trol was significantly more prevalent in PD-MBI302
with a disease duration >1 year, compared to newly303
diagnosed PD-MBI; 3) MBI showed a tendency to304
increase with disease progression, particularly for305
Social Inappropriateness and Abnormal Perception;306
4) when compared to PDw, the presence of MBI in307
newly diagnosed patients was significantly associated308
with motor disability and antidepressant treatment,309
while in patients with a disease duration >1 year PD-310
MBI was associated with motor impairment; 5) lastly,311
there was no association of MCI with MBI, also after312
stratifying by disease duration.313
There are currently no data regarding MBI in PD314
after stratification by disease duration: about half of315
the subjects with disease duration >1 year had MBI,316
which was also found in over one/third of newly317
diagnosed PD. Overall, these data indicated a cumu-318
lative prevalence of MBI in PD of 84.1% (95% CI319
80.3–87.5), thus confirming previous reports in non-320
demented, non-PD subjects [10].321
The result of the present study confirmed that322
MBI domains, including depression and anxiety (i.e.,323
Affective Dysregulation), and apathy (i.e., Decreased324
Motivation), are very frequent in nondemented sub-325
jects with PD with and without MCI [8, 25].326
Depression and anxiety have been described as sig-327
nificant factors, which are associated with cognitive328
decline [25, 26], both representing the strongest pre-329
dictors of a poor quality of life in PD patients [27].330
Apathy, which is often associated with lower global331
cognition and depression in PD [28], in subjects with332
PD-MCI is significantly related with executive func-333
tioning [29]. This indirectly supports the hypothesis334
that the presence of motivational disorders in these335
patients is related to frontal-striatal dysregulation336
[29].337
When stratifying PD subjects according to dis-338
ease duration (in order to evaluate differences in339
MBI domains), those with longer duration of dis-340
ease displayed a significantly higher percentage of341
symptoms, which were related to irritability, agi-342
tation, and aberrant motor behavior (i.e., Impulse343
Dyscontrol) when compared to newly diagnosed PD- 344
MBI individuals. There are few data in the literature 345
describing the frequency of these neuropsychiatric 346
symptoms in PD: in a Serbian study, irritability was 347
present in 19.4% of PD patients, agitation in approxi- 348
mately 10.8%, and aberrant motor behavior in a very 349
small percentage (2.5%). The authors of this study 350
also observed that the cluster of neuropsychiatric 351
symptoms (including agitation, irritability, disinhi- 352
bition, and psychosis) was associated with a higher 353
UPDRS-ME score [30]. Regarding the four other 354
MBI domains (i.e., Decreased Motivation, Affective 355
Dysregulation, Social Inappropriateness, and Abnor- 356
mal Perception), the two PD-MBI samples (newly 357
diagnosed versus patients with a disease duration >1 358
year) did not show any significant difference. Over- 359
all, the above results suggest that MBI, as a surrogate 360
measure of neuropsychiatric symptoms in PD, has 361
poor specificity for the identification of the early 362
phase of the disease. 363
MBI domains across H&Y stages in PD were also 364
evaluated. Excluding Affective Dysregulation (i.e., 365
depression, anxiety, and euphoria), very frequent and 366
early nonmotor symptoms in PD [25], MBI showed a 367
tendency to increase with disease progression and dis- 368
ability, with significant results appearing for Social 369
Inappropriateness and Abnormal Perception. The 370
results of the present study confirm previous find- 371
ings, demonstrating that neuropsychiatric symptoms 372
are more frequent in advanced disease, and that the 373
main correlates/risk factors for psychosis in PD are 374
increasing severity and duration of PD [3]. 375
Thereafter, associated factors for MBI in PD were 376
examined: a significant association of MBI with H&Y 377
score and antidepressant drug use was observed in 378
newly diagnosed subjects, while in patients with a 379
disease duration >1 year MBI related only to UPDRS- 380
ME. Overall, the results of the present report are in 381
line with those previously described, confirming that 382
NPS (including depression, anxiety, and psychosis) 383
are associated with motor impairment [31]. 384
Lastly, the association between MBI and MCI 385
was evaluated. Although the latter was more preva- 386
lent overall in PD-MBI with a disease duration >1 387
year versus PDw and newly diagnosed PD-MBI sub- 388
jects, it was significantly associated with MBI only 389
at univariate analysis and in the whole MBI group. 390
However, multivariate analysis did not reveal any sig- 391
nificant association with MCI and MBI for the whole 392
group as well as when PD-MBI was stratified accord- 393
ing to disease duration. These results suggest that, 394
even showing a minor association, MCI and MBI 395
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represent very frequent non-motor features of early396
PD, which could have different etiologies and deter-397
minants. Nonetheless, we cannot exclude a possible398
lack of statistical power, type II error, when anal-399
ysis was stratified for disease duration due to the400
small number of PDw patients included. Accord-401
ingly, future prospective research conducted in larger402
cohorts is required in order to clarify the association403
between MCI and MBI in nondemented PD patients,404
their risk factors, and their effects on PD prognosis.405
This study has several strengths. It was designed406
to specifically evaluate the prevalence and corre-407
lates of MBI in a relatively large sample of PD408
patients, including newly diagnosed patients. Patients409
underwent a comprehensive cognitive and behavioral410
assessment using: level II MDS diagnostic criteria411
for PD-MCI [5] and the NPI, a widely used and vali-412
dated questionnaire for cognitive impairment-related413
behavioral symptoms, in order to define the MBI con-414
struct [11].415
However, there are some methodological issues.416
Firstly, since the sample was drawn from a special-417
ized setting, a selection bias (i.e., an overestimation418
of MBI frequency) cannot be excluded. Secondly,419
the use of NPI—a caregiver-based interview—has420
raised the possibility of reporting bias (i.e., under- or421
overestimation of behavioral information). Thirdly,422
MBI was defined using the NPI as previously sug-423
gested [10]. This definition takes little account of424
those symptoms belonging to the impulse dyscon-425
trol spectrum, which are specific of PD. Therefore,426
the frequency and relationships of this cluster of427
neuropsychiatric symptoms in individuals with PD428
may be underestimated in this study. Fourthly,429
although analyses were adjusted for major con-430
founders, unmeasured confounding (i.e., premorbid431
personality traits) cannot be excluded. Fifthly, con-432
cerning the potential role of dopaminergic treatment,433
it was not possible to evaluate the prevalence of434
MBI in drug na¨ive PD subjects due to the small435
sample included. Nonetheless, LED was not asso-436
ciated with MBI in newly diagnosed PD, but, as437
expected, after univariate analysis it was associated438
with PD-MBI in PD patients with disease duration439
>1 year. However, this result disappeared after mul-440
tivariate analysis. Future studies conducted on large441
untreated populations are required to evaluate the role442
of dopaminomimetics in determining MBI profiles in443
PD subjects. Lastly, the cross-sectional study design444
precludes making causal inferences about the rela-445
tionship between putative associated factors and the446
study outcome.447
In conclusion, the results of this study suggest that 448
MBI in subjects with PD is rather frequent, occur- 449
ring in over 80% of subjects and in approximately 450
one-third of newly diagnosed patients. Behavioral 451
impairment in PD subjects is probably linked to motor 452
progression and disability, in the absence of a sig- 453
nificant relationship with MCI. Due to the relative 454
high frequency of MBI in newly diagnosed patients, 455
its early identification, characterization and appro- 456
priate treatment should be implemented. However, 457
the MBI construct seems to be rather unreliable for 458
PD, due to its low specificity in characterizing the 459
early phase of the disease. Further analysis, with the 460
recently proposed MBI Checklist [32], conducted in 461
large prospective cohorts will clarify the role of MBI 462
in predicting conversion to dementia in PD. 463
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